1. World Health Organization Influenza vaccines. Wkly Epidemiol Rec. 2005;80:279–287. [PubMed] 2. Demicheli V, Rivetti D, Deeks JJ, Jefferson TO. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2004;3:CD001269. [PubMed] 3. Rose GW, Cooper CL. Fluarix™, inactivated split-virus influenza vaccine. Expert Opin Biol Ther. 2006;6:301–310. [PubMed] 4. Lin YP, Gregory V, Bennett M, Hay A. Recent changes among human influenza viruses. Virus Res. 2004;103:47–52. [PubMed] 5. Kanegae Y, Sugita S, Endo A, et al. Evolutionary pattern of the hemagglutinin gene of influenza B viruses isolated in Japan: cocirculating lineages in the same epidemic season. J Virol. 1990;64:2860–2865. [PMC free article] [PubMed] 6. Rota PA, Wallis TR, Harmon MW, Rota JS, Kendal AP, Nerome K. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology. 1990;175:59–68. [PubMed] 7. Rota PA, Hemphill ML, Whistler T, Regnery HL, Kendal AP. Antigenic and genetic characterization of the hemagglutinin of recent cocirculating strains of influenza B virus. J Gen Virol. 1992;73:2737–2742. [PubMed] 8. Munoz ET, Deem MW. Epitope analysis for influenza vaccine design. Vaccine. 2005;23:1144–1148. [PubMed]
9. Ferro VA. Improved design of the annual influenza vaccine using epitope analysis. Expert Rev Vaccines. 2005;4:157–161.
10. Centers for Disease Control and Prevention Prevention and Control of Influenza Recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Morb. Mortal. Wkly. Rep. 2007;56 No. RR 6. [PubMed] 13. Langley JM, Faughnan ME. Prevention of influenza in the general population. CMAJ. 2004;171:1213–1222. [PMC free article] [PubMed] 14. Skowronski DM, Masaro C, Kwindt TL, et al. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005–2006 season of dual A and B vaccine mismatch in Canada. Vaccine. 2007;25:2842–2851. [PubMed]
15. Bouveret N, Ervin J, Hull S, Desrosiers C, Allard M, Fries L. Baltimore, MD: Safety and immunogenicity evaluation of Fluviral™ (FluLaval™ in US) influenza vaccine in subjects 50 years and older. Tenth Annual Conference on Vaccine Research, April 30–May 2, 2007. (NCT: 00232947.
16. Desrosiers C, Bouveret N, Girard B, et al. Washington, DC: Safety and immunogenicity of new formulations of a split inactivated influenza vaccine in healthy subjects 50 years old and over. 4th Annual Conference on Vaccine, November 17.
18. Hehme NW, Künzel W, Petschke F, et al. Ten years of experience with the trivalent split-influenza vaccine, Fluarix™ Clin Drug Invest. 2002;22:751–769.
20. Van Hoecke C, Prikazsky V, Ütö I, et al. Immunogenicity of an inactivated split influenza vaccine in institutionalized elderly patients. Gerontology. 1996;42:190–198. [PubMed] 21. Künzel W, Glathe H, Engelmann N, et al. Kinetics of humoral antibody response to trivalent inactivated split influenza vaccine in subjects previously vaccinated or vaccinated for the first time. Vaccine. 1996;14:1108–1110. [PubMed] 22. Künzel W, Engelmann H, D’Hondt E. Immune response to influenza vaccination [letter] Lancet. 1994;343:173. [PubMed] 23. Treanor JJ, Campbell JD, Brady RC, et al. Rapid licensure of a new, inactivated influenza vaccine in the United States. Human Vaccines. 2005;1:239–244. NCT: 00100399. [PubMed]
24. Campbell JD, Chambers C, Brady R, et al. Baltimore, MD: A phase III study to evaluate the immunogenicity and safety of Fluarix™, compared to Fluzone® in adults in the U.S. Tenth Annual Conference on Vaccine Research sponsored by the National Foundation for Infectious Diseases, April 30–May 2, NCT: 00197288.
25. Beran J, Vesikari T, Devaster JM, Innis B. Washington, DC: Efficacy of an inactivated split-virus influenza vaccine. 48th ICAAC (American Society for Microbiology)/ 46th IDSA (Infectious Diseases Society of America) Annual Joint Meeting, October 25–28, NCT: 00363870.
26. Schmidt-Ott R, Schwarz T, Haas R, et al. Immunogenicity and reactogenicity of a trivalent influenza split vaccine in previously unvaccinated children aged 6-9 and 10-13 years. Vaccine. 2007;26:32–40. NCT: 00372255. [PubMed] 27. Nichol KL. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine. 2003;21:1769–1775. [PubMed] 28. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med. 1994;331:778–784. [PubMed] 29. Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA. 1994;272:1661–1665. [PubMed] 31. Osterhaus AD. Pre- or post-pandemic influenza vaccine? Vaccine. 2007;25:4983–4984. [PubMed] 32. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med. 2008;358:261–273. [PubMed] 34. Hehme N, Engelmann H, Kuenzel W, Neumeier E, Saenger R. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res. 2004;103:163–171. (NCT: 00453986) [PubMed] 35. Hehme N, Engelmann H, Kuenzel W, Neumeier E, Saenger R. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol. 2002;191:203–208. (NCT: 00453986) [PubMed]
36. Hehme N, Kuhn A, Mueller M, et al. Vienna, Austria: Whole virus alum-adjuvanted pandemic vaccine: safety and immunogenicity data on a vaccine formulated with H5N1. International Conference on Influenza Vaccines for the World – IVW2006, October 18–20, NCT: 00306995.
37. Hovden AO, Cox RJ, Haaheim LR. Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice. Scand J Immunol. 2005;62:36–44. [PubMed] 38. Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines. 2007;6:723–739. [PubMed] 39. Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet. 2007;370:580–589. (NCT: 00309634) [PubMed] 40. Reid AH, Fanning TG, Hultin JV, Taubenberger JK. Origin and evolution of the 1918 “Spanish” influenza virus hemagglutinin gene. Proc Natl Acad Sci USA. 1999;96:1651–1656. [PubMed]
42. ECDC Technical Report: Expert Advisory Groups on Human H5N1 Vaccines. Stockholm: Public Health and Operational Questions; 2007.
44. Wood JM, Robertson JS. Reference viruses for seasonal and pandemic influenza vaccine preparation. Influenza other Respir Viruses. 2007;1:5–9. [PubMed] 45. Leroux-Roels I, Bernhard R, Gerard P, Dramé M, Hanon E, Leroux-Roels G. Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS ONE. 2008;3 NCT: 00309634. [PMC free article] [PubMed]
46. Baras B, Stittelaar S, Simon J, et al. Hong Kong: Immunization with low dose adjuvanted split H5N1 pandemic vaccine protects ferrets against homologous challenge. IX International Symposium on Respiratory Viral Infections, March 3–6.
47. Baras B, Stittelaar KJ, Simon JH, et al. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS ONE. 2008;3:e1401. [PMC free article] [PubMed]
48. Chu DW, Dramé M, Hwang SJ, et al. Singapore: Safety and immunogenicity of an AS adjuvanted H5N1 prepandemic influenza vaccine. A phase II study in a large population of Asian adults. X International Symposium on Respiratory Viral Infections, February 28–March 2 NCT: 00449670.
49. Heijmans S, De Meulemeester M, Reynders P, et al. Boston, MA: AS03 adjuvanted prepandemic influenza vaccine: high immunogenicity in the elderly. Data presented at the 2nd Vaccine Congress, December 7–9, NCT: 00397215.
50. Ballester A, Garcés-Sánchez M, Planelles C, et al. Washington, DC: Immunogenicity evaluation of an AS03-adjuvanted H5N1 prepandemic candidate vaccine in children aged 3–9 years. 48th ICAAC (American Society for Microbiology)/46th IDSA (Infectious Diseases Society of America) Annual Join Meeting, October 25–28, NCT: 00502593.
51. Rümke HC, Bayas JM, de Juanes JR, et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine. 2008;26:2378–2388. NCT: 00319098. [PubMed]
52. Ballester A, Garcés Sánchez M, Planelles Cantarino MV, et al. Graz, Austria: Pediatric safety evaluation of an AS-adjuvanted H5N1 prepandemic vaccine in children aged 6–9 years. A phase II study. 26th Annual Meeting of European Society Pediatric Infectious Disease, May 13–16, NCT: 00502593.
53. Ballester A, Garcés Sánchez M, Planelles Cantarino MV, et al. Malaysia: Pediatric safety evaluation of an AS-adjuvanted H5N1 prepandemic candidate vaccine in children aged 3-9 years. A phase II study. 13th International Congress Infectious Diseases, Kuala Lumpur, June 19–22, NCT: 00502593.
54. Longini IM, Nizam A, Xu S, et al. Containing pandemic influenza at the source. Science. 2005;309:1083–1087. [PubMed] 55. Ferguson NM, Cummings DAT, Fraser C, et al. Strategies for mitigating an influenza pandemic. Nature. 2006;442:448–452. [PubMed] 56. Ciofi degli Atti ML, Merler S, Rizzo C, et al. Mitigation measures for pandemic influenza in Italy: an individual based model considering different scenarios. PLoS ONE. 2008;3:e1790. [PMC free article] [PubMed] 57. Webster RG, Govorka EA. H5N1 influenza – continuing evolution and spread. N Engl J Med. 2006;355:2174–2177. [PubMed]